SIGA (SIGA) 10-K 12 Mar 24 2023 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2023	Feb. 15, 2024	Jun. 30, 2023
Document Information [Line Items]
Entity Central Index Key	0001010086
Entity Registrant Name	Siga Technologies INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Document Transition Report	false
Entity File Number	0-23047
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	13-3864870
Entity Address, Address Line One	31 East 62nd Street
Entity Address, Postal Zip Code	10065
Entity Address, City or Town	New York
Entity Address, State or Province	NY
City Area Code	212
Local Phone Number	672-9100
Title of 12(b) Security	common stock, $.0001 par value
Trading Symbol	SIGA
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 230,952,256
Entity Common Stock, Shares Outstanding		71,091,616
Auditor Firm ID	238
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	Florham Park, New Jersey

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 150,145,844	$ 98,790,622
Accounts receivable	21,130,951	45,406,960
Inventory	64,218,337	39,273,090
Prepaid expenses and other current assets	3,496,028	2,315,672
Total current assets	238,991,160	185,786,344
Property, plant and equipment, net	1,331,708	1,848,314
Deferred tax asset, net	11,048,118	6,250,385
Goodwill	898,334	898,334
Other assets	2,083,535	252,546
Total assets	254,352,855	195,035,923
Current liabilities
Accounts payable	1,456,316	3,355,268
Accrued expenses and other current liabilities	10,181,810	6,304,061
Deferred IV TPOXX® revenue	20,788,720	10,548,720
Income tax payable	21,690,899	1,309,672
Total current liabilities	54,117,745	21,517,721
Other liabilities	3,376,203	3,358,160
Total liabilities	57,493,948	24,875,881
Commitments and contingencies (Note 12)
Stockholders' equity
Common stock ($.0001 par value, 600,000,000 shares authorized, 71,091,616 and 72,675,190 issued and outstanding at December 31, 2023 and December 31, 2022, respectively)	7,109	7,268
Additional paid-in capital	235,795,420	233,957,767
Accumulated deficit	(38,943,622)	(63,804,993)
Total stockholders' equity	196,858,907	170,160,042
Total liabilities and stockholders' equity	$ 254,352,855	$ 195,035,923

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	600,000,000	600,000,000
Common stock, shares issued (in shares)	71,091,616	72,675,190
Common stock, shares outstanding (in shares)	71,091,616	72,675,190

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues
Total revenues	$ 139,917,220	$ 110,775,610	$ 133,670,454
Operating expenses
Cost of sales and supportive services	17,825,090	10,432,561	16,601,880
Selling, general and administrative	22,043,023	35,117,241	18,033,581
Research and development	16,427,942	22,525,642	9,942,194
Total operating expenses	56,296,055	68,075,444	44,577,655
Operating income	83,621,165	42,700,166	89,092,799
Gain from change in fair value of warrant liability	0	400,663	117,770
Other income, net	4,155,508	1,031,903	101,172
Income before income taxes	87,776,673	44,132,732	89,311,741
Provision for income taxes	(19,707,847)	(10,227,926)	(19,860,975)
Net and comprehensive income	$ 68,068,826	$ 33,904,806	$ 69,450,766
Basic earnings per share (in dollars per share)	$ 0.95	$ 0.46	$ 0.92
Diluted earnings per share (in dollars per share)	$ 0.95	$ 0.46	$ 0.91
Weighted average shares outstanding: basic (in shares)	71,362,209	72,929,550	75,322,194
Weighted average shares outstanding: diluted (in shares)	71,679,270	73,546,501	76,402,716
Product Sales and Supportive Services [Member]
Revenues
Total revenues	$ 130,668,209	$ 86,661,583	$ 126,802,536
Research and Development [Member]
Revenues
Total revenues	$ 9,249,011	$ 24,114,027	$ 6,867,918

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2020	77,195,704
Balance at Dec. 31, 2020	$ 7,720	$ 224,978,430	$ (95,192,881)	$ 0	$ 129,793,269
Net income			69,450,766		69,450,766
Repurchase of common stock (in shares)	(3,787,683)
Repurchase of common stock	$ (379)		(26,021,140)		(26,021,519)
Issuance of common stock upon vesting of RSUs (in shares)	162,876
Issuance of common stock upon vesting of RSUs	$ 16	(16)			0
Payment of common stock tendered for employee stock-based compensation tax obligations (in shares)	(27,295)
Payment of common stock tendered for employee stock-based compensation tax obligations	$ (3)	(173,915)			(173,918)
Stock-based compensation		1,265,809			1,265,809
Balance (in shares) at Dec. 31, 2021	73,543,602
Balance at Dec. 31, 2021	$ 7,354	226,070,308	(51,763,255)	0	174,314,407
Net income			33,904,806		33,904,806
Repurchase of common stock (in shares)	(1,823,738)
Repurchase of common stock	$ (182)		(13,006,149)		(13,006,331)
Issuance of common stock upon vesting of RSUs (in shares)	132,396
Issuance of common stock upon vesting of RSUs	$ 13	(13)			0
Payment of common stock tendered for employee stock-based compensation tax obligations (in shares)	(1,973)
Payment of common stock tendered for employee stock-based compensation tax obligations		(12,533)			(12,533)
Stock-based compensation		1,779,310			1,779,310
Issuance of common stock upon exercise of warrants (in shares)	824,903
Issuance of common stock upon exercise of warrants	$ 83	6,120,695			6,120,778
Cash dividend ($0.45 per share)			(32,940,395)		$ (32,940,395)
Issuance of common stock upon exercise of stock options (in shares)					0
Balance (in shares) at Dec. 31, 2022	72,675,190
Balance at Dec. 31, 2022	$ 7,268	233,957,767	(63,804,993)	0	$ 170,160,042
Net income			68,068,826		68,068,826
Repurchase of common stock (in shares)	(1,736,822)
Repurchase of common stock	$ (174)		(11,072,337)		(11,072,511)
Issuance of common stock upon vesting of RSUs (in shares)	144,576
Issuance of common stock upon vesting of RSUs	$ 15	(15)			0
Payment of common stock tendered for employee stock-based compensation tax obligations		(214,794)			(214,794)
Stock-based compensation		2,052,462			2,052,462
Cash dividend ($0.45 per share)			(32,135,118)		$ (32,135,118)
Issuance of common stock upon exercise of stock options (in shares)	8,672				100,000
Issuance of common stock upon exercise of stock options					$ 0
Balance (in shares) at Dec. 31, 2023	71,091,616
Balance at Dec. 31, 2023	$ 7,109	$ 235,795,420	$ (38,943,622)	$ 0	$ 196,858,907

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Stockholders' Equity (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash dividend per share (in dollars per share)	$ 0.45	$ 0.45

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net income	$ 68,068,826	$ 33,904,806	$ 69,450,766
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and other amortization	538,293	517,643	522,368
Gain on change in fair value of warrant liability	0	(400,663)	(117,770)
Stock-based compensation	2,052,462	1,779,310	1,265,809
Write down of inventory, net	579,239	201,472	618,771
Deferred income taxes (benefit) provision	(4,797,733)	(3,827,778)	121,446
Changes in assets and liabilities:
Accounts receivable	24,276,009	38,243,490	(80,310,187)
Inventory	(25,524,485)	(19,964,183)	136,369
Prepaid expenses and other assets	(3,011,346)	171,811	48,963
Accounts payable, accrued expenses and other liabilities	1,996,838	1,533,804	1,470,614
Income tax payable	20,381,228	(17,897,370)	18,287,487
Deferred IV TPOXX® revenue	10,240,000	7,348,720	0
Net cash provided by operating activities	94,799,331	41,611,062	11,494,636
Cash flows from investing activities:
Capital expenditures	(21,686)	0	(50,620)
Cash used in investing activities	(21,686)	0	(50,620)
Cash flows from financing activities:
Payment of employee tax obligations for common stock tendered	(214,794)	(12,533)	(173,918)
Repurchase of common stock	(11,072,511)	(13,006,331)	(26,021,519)
Payment of dividend	(32,135,118)	(32,940,395)	0
Cash used in financing activities	(43,422,423)	(45,959,259)	(26,195,437)
Net increase/(decrease) in cash and cash equivalents	51,355,222	(4,348,197)	(14,751,421)
Cash and cash equivalents at the beginning of period	98,790,622	103,138,819	117,890,240
Cash and cash equivalents at end of period	150,145,844	98,790,622	103,138,819
Supplemental disclosure of cash flows information:
Non-cash lease right-of-use asset and associated liability	0	0	733,715
Conversion of warrant to common stock	0	6,120,778	0
Issuance of common stock upon cashless exercise	87,540	0	0
Cash income taxes paid, net	$ 3,500,873	$ 31,372,881	$ 1,063,744

Note 1 - Organization and Basis

Note 1 - Organization and Basis of Presentation	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Organization and Basis of Presentation Description of Business SIGA Technologies, Inc. (“SIGA” or the “Company”) is a commercial-stage pharmaceutical company. The Company sells its lead product, TPOXX® (“oral TPOXX®,” also known as "tecovirimat" in certain international markets), to the U.S. government and international governments (including government affiliated entities). Additionally, the Company sells the intravenous formulation of TPOXX® ("IV TPOXX®") to the U.S. government. TPOXX® is an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. On July 13, 2018, 2013. In connection with IV TPOXX®, SIGA announced on May 19, 2022 In addition to being approved by the FDA, oral TPOXX® (tecovirimat) has regulatory approval with the European Medicines Agency ("EMA"), Health Canada and the Medicines and Healthcare Products Regulatory Agency ("MHRA") of the United Kingdom. The EMA and MHRA approved label indication covers the treatment of smallpox, monkeypox ("mpox"), cowpox, and vaccinia complications following vaccination against smallpox. The Health Canada approved label indication covers the treatment of smallpox. With respect to the regulatory approvals by the EMA, MHRA and Health Canada, oral tecovirimat represents the same formulation that was approved by the FDA in July 2018

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Use of Estimates Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the periods reported. The most significant estimates include the variables used in the calculation of reported amounts of revenue recognized over time, and the valuation of deferred tax assets. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the financial statements in the period they are determined to be necessary. Actual results could differ from these estimates. Basis of Presentation and Consolidation The accompanying consolidated financial statements include the accounts of SIGA Technologies, Inc. and its wholly owned subsidiaries. All inter-company accounts and transactions have been eliminated in consolidation. The consolidated financial statements and related disclosures are presented in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and reflect the consolidated financial position, results of operations and cash flows for all periods presented. Reclassifications Certain reclassifications have been made to prior year amounts to conform to the current year's presentation. Cash Equivalents The Company considers all highly liquid investments with original maturities of three Concentration of Credit Risk The Company has cash in bank accounts that exceeds the Federal Deposit Insurance Corporation insured limits. The Company has not no Collection of all receivables from international government sales is coordinated through the International Promotion Agreement with Meridian (see Note 3 Accounts Receivable Accounts receivable are recorded net of provisions for doubtful accounts. At December 31, 2023 2022 December 31, 2023 four a Note 3 December 31, 2023 2022 Inventory Inventory is stated at the lower of cost or net realizable value. The cost is determined using the first first may not Property, Plant and Equipment Property, plant and equipment are stated at cost, net of accumulated depreciation. Depreciation and amortization are provided on a straight-line method over the estimated useful lives of the various asset classes. The estimated useful lives are as follows: five three seven Warrant Liability The Company accounted for warrants in accordance with the authoritative guidance which requires that free-standing derivative financial instruments with certain cash settlement features be classified as assets or liabilities at the time of the transaction, and recorded at their fair value. Fair value was estimated using model-derived valuations. Any changes in the fair value of the derivative instruments were reported in earnings or loss as long as the derivative contracts were classified as assets or liabilities. During 2022, December 31, 2022. The following table presents changes in the liability-classified warrant: Fair Value of liability-classified warrant Warrant liability at December 31, 2021 $ 6,521,441 Decrease in fair value of warrant liability (400,663 ) Exercise of warrants (6,120,778 ) Warrant liability at December 31, 2022 $ - Revenue Recognition The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers 606” Performance Obligations 606. December 31, 2023 Note 3 Contract modifications may not The Company’s performance obligations are satisfied over time as work progresses or at a point in time. A portion of the Company’s revenue is derived from long-term contracts that span multiple years. All of the Company’s revenue related to current research and development performance obligations is recognized over time, because the customer simultaneously receives and consumes the benefits provided by the services as the Company performs these services. The Company recognizes revenue related to these services based on the progress toward complete satisfaction of the performance obligation and measures this progress under an input method, which is based on the Company’s cost incurred relative to total estimated costs. Under this method, progress is measured based on the cost of resources consumed (i.e., cost of third third Contract Estimates Contract estimates are based on various assumptions to project the outcome of future events that often span multiple years. These assumptions include: labor productivity; the complexity of the work to be performed; external factors such as customer behavior and potential regulatory outcomes; and the performance of subcontractors, among other variables. The nature of the work required to be performed on many of the Company’s performance obligations and the estimation of total revenue and cost at completion may not not A significant change in one Contract Balances may December 31, 2023 December 31, 2023 Remaining Performance Obligations not December 31, 2023 three Leases The Company accounts for leases in accordance with ASC 842, Leases 842” The Company determines if an arrangement is a lease at inception. Leases with an initial term less than one not one Operating lease liabilities are recognized at the commencement date based on the present value of future minimum lease payments over the lease term. ROU assets are recognized based on the corresponding lease liabilities adjusted for qualifying initial direct costs, prepaid or accrued lease payments and unamortized lease incentives. The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease. Lease terms may Research and Development Research and development expenses include costs directly and indirectly attributable to the conduct of research and development programs, and performance pursuant to certain customer contracts, including employee related costs, materials, supplies, depreciation and maintenance of equipment, the cost of services provided by outside contractors, including services related to the Company’s clinical trials and facility costs, such as rent, utilities, and general support services. All costs associated with research and development are expensed as incurred. Costs related to the acquisition of technology rights, for which development work is still in process, and that have no Goodwill The Company evaluates goodwill for impairment at least annually or as circumstances warrant. The impairment review process compares the fair value of the reporting unit in which goodwill resides to its carrying value. The Company operates as one one Share-based Compensation Stock-based compensation expense for all share-based payment awards made to employees and directors is determined on the grant date; for option awards, fair value was estimated using the Black-Scholes model. These compensation costs are recognized net of an estimated forfeiture rate over the requisite service periods of the awards. Forfeitures are estimated on the date of the respective grant and revised if actual or expected forfeiture activity differs from original estimates. The fair value of cash-settled restricted stock unit ("RSU") awards is determined by the value of our common stock and is recognized based on the portion of the requisite service period satisfied as of each valuation date. The fair valuation of the cash-settled awards changes based on changes in our common stock price. The portion of cash-settled RSUs that is recognized based on service period is reflected in accrued expenses and other current liabilities in our consolidated balance sheet. Increases (or decreases) in accrued expenses result in adjustments to earnings for the associated valuation updates. Income Taxes The Company recognizes income taxes utilizing the asset and liability method of accounting for income taxes. Under this method, deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities at enacted tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is established if it is more likely than not not may not fifty not Repurchase of shares When shares recognized as equity are repurchased, the amount of the consideration paid, which includes directly attributable costs, is recognized as a deduction from equity. The excess of the purchase price above par value of repurchased shares that are retired is presented as an increase to accumulated deficit (or a reduction of retained earnings, if any). Earnings (Loss) per Share Basic earnings per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the period, assuming potentially dilutive common shares from option exercises, RSUs, warrants and other incentives had been issued and any proceeds received in respect thereof were used to repurchase common stock at the average market price during the period. The assumed proceeds used to repurchase common stock is the sum of the amount to be paid to the Company upon exercise of options and warrants and the amount of compensation cost attributed to future services not Fair Value of Financial Instruments The carrying value of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and other current liabilities approximates fair value due to the relatively short maturity of these instruments. The measurement of fair value requires the use of techniques based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions. The inputs create the following fair value hierarchy: • Level 1 • Level 2 not • Level 3 third There were no 2023 2022 December 31, 2023 December 31, 2022 1 no 2 December 31, 2023 December 31, 2022 2 no 3 December 31, 2023 December 31, 2022 For the years ended December 31, 2023, 2022 2021 Loss Contingencies The Company is subject to certain contingencies arising in the ordinary course of business. The Company records accruals for these contingencies to the extent that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, that amount is accrued. Alternatively, when no Segment Information The Company is managed and operated as one not not one Recent Accounting Pronouncements In November 2023, No. 2023 07, 280 not December 15, 2023, December 15, 2024, no In December 2023, 2023 09, 2023 09 December 15, 2024, may not

Note 3 - Procurement Contracts

Note 3 - Procurement Contracts and Research Agreements	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Procurement Contract and Research Agreements [Text Block]	3. 19C On September 10, 2018, October 2023, 19C December 31, 2023 "19C may ten 19C The base period of performance specifies potential payments of approximately $51.7 million for the following activities: payments of approximately $11.1 million for the delivery of approximately 35,700 courses of oral TPOXX® to the Strategic Stockpile; payments of $8.0 million for the manufacture of 10,000 courses (as currently defined within the contract as being 28 December 31, 2023 December 31, 2021, 2022, The options that have been exercised to date provide for payments up to approximately $407.1 million. There are exercised options for the following activities: payments up to $337.7 million for the manufacture and delivery of up to 1.1 million courses of oral TPOXX®; payments up to $51.2 million for the manufacture of courses of IV FDP, of which $20.4 million of payments relate to the manufacture of IV BDS to be used in the manufacture of IV FDP; payments of up to approximately $3.6 million to fund post-marketing activities for IV TPOXX®; and payments of up to $14.6 million for funding of post-marketing activities for oral TPOXX®. As of December 31, 2023 fourth 2023; December 31, 2023 first two 2024 February 29, 2024, Unexercised options specify potential payments up to approximately $143.7 million in total (if all such options are exercised), of which approximately $5.6 million relates to supportive activities that we currently do not The options related to IV TPOXX® are divided into two may none 19C three three not two three two three 32,000 Revenues in connection with the 19C 19C December 31, 2023 2022 December 31, 2023 2022 U.S. Department of Defense Procurement Contracts On May 12, 2022, #1" #1 second 2022, #1. third 2022, September 2022 On September 28, 2022, #2" #2 In March 2023, March 2023 #2 fourth 2023 In February 2024, #2 International Procurement Contracts In 2023, five one one first two 2024 February 29, 2024, six 13 October 2022. February 2024. In addition to the above-mentioned orders and deliveries, the Company has a contract with the CDND under which the CDND has an option until December 31, 2025, April 2020 In 2022, 13 2022, 2022, 2023. Under the International Promotion Agreement, Meridian is the counterparty in connection with international contracts for oral TPOXX® and SIGA is responsible for manufacture and delivery of any oral TPOXX® purchased thereunder. Under the terms of the International Promotion Agreement, as amended, which has an initial term that expires on May 31, 2024, not Sales to international customers pursuant to the International Promotion Agreement are invoiced and collected by Meridian, and such collections are remitted, less Meridian's fees, to the Company under a quarterly process specified in the International Promotion Agreement. The fee Meridian retains pursuant to the International Promotion Agreement is a specified percentage of the collected proceeds of sales of oral TPOXX®, net of certain expenses, for calendar years in which customer collected amounts net of such expenses are less than or equal to a specified threshold, and a higher specified percentage of such collected net proceeds for calendar years in which such net collected amounts exceed the specified threshold. We exceeded the specified threshold in 2022 2022. Revenue in connection with international procurement contracts for the delivery of product are recognized at a point in time on a gross basis, as the Company acts as the principal in the transaction. During the year ended December 31, 2023 December 31, 2022 Research Agreements and Grants In July 2019, December 31, 2023 December 31, 2023 no December 31, 2023 2022 Contracts and grants include, among other things, options that may may not may not

Note 4 - Inventory

Note 4 - Inventory	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Inventory Disclosure [Text Block]	4. Inventory Inventory consisted of the following: As of December 31, 2023 December 31, 2022 Raw materials $ 8,061,800 $ 6,370,581 Work in-process 53,649,859 27,038,845 Finished goods 2,506,678 5,863,664 Inventory $ 64,218,337 $ 39,273,090

Note 5 - Property, Plant and Eq

Note 5 - Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property, Plant and Equipment Property, plant and equipment consisted of the following: As of December 31, 2023 December 31, 2022 Leasehold improvements $ 2,420,028 $ 2,420,028 Computer equipment 468,937 449,143 Furniture and fixtures 347,045 347,045 Operating lease right-of-use asset 3,678,647 3,678,647 6,914,657 6,894,863 Less-accumulated depreciation (5,582,949 ) (5,046,549 ) Property, plant and equipment, net $ 1,331,708 $ 1,848,314 Depreciation and amortization expense on property, plant, and equipment was $0.5 million for each of the years ended December 31, 2023 2022 2021

Note 6 - Accrued Expenses and O

Note 6 - Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	6. Accrued Expenses Accrued expenses and other current liabilities consisted of the following: As of December 31, 2023 December 31, 2022 Inventory $ 3,300,985 $ 31,160 Compensation 2,792,874 2,378,035 Other 2,659,608 1,277,779 Lease liability, current portion 564,009 528,170 Professional fees 445,653 536,997 Research and development vendor costs 418,681 1,551,920 Accrued expenses and other current liabilities $ 10,181,810 $ 6,304,061

Note 7 - Per Share Data

Note 7 - Per Share Data	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Earnings Per Share [Text Block]	7. Per Share Data The Company computes, presents and discloses earnings per share in accordance with the authoritative guidance which specifies the computation, presentation and disclosure requirements for earnings per share of entities with publicly held common stock or potential common stock. The objective of basic EPS is to measure the performance of an entity over the reporting period by dividing income (loss) by the weighted average shares outstanding. The objective of diluted EPS is consistent with that of basic EPS, except that it also gives effect to all potentially dilutive common shares outstanding during the period. The following is a reconciliation of the basic and diluted earnings (loss) per share computation: Year Ended December 31, 2023 2022 2021 Net income for basic earnings per share $ 68,068,826 $ 33,904,806 $ 69,450,766 Less: Change in fair value of warrants — 400,663 117,770 Net income, adjusted for change in fair value of warrants for diluted earnings per share $ 68,068,826 $ 33,504,143 $ 69,332,996 Weighted-average shares 71,362,209 72,929,550 75,322,194 Effect of potential common shares 317,061 616,951 1,080,522 Weighted-average shares: diluted 71,679,270 73,546,501 76,402,716 Earnings per share: basic $ 0.95 $ 0.46 $ 0.92 Earnings per share: diluted $ 0.95 $ 0.46 $ 0.91 For the years ended December 31, 2023, December 31, 2022 December 31, 2021, December 31, 2022 December 31, 2021, not December 31, 2023, 2022 2021 December 31, 2023, 2022 2021,

Note 8 - Stockholders' Equity

Note 8 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Equity [Text Block]	8. Stockholders’ Equity On December 31, 2023 December 31, 2023 2022 On August 2, 2021, December 31, 2023. fourth 2021. December 31, 2023 December 31, 2023 On December 31, 2023, On May 4, 2023 June 1, 2023 May 16, 2023

Note 9 - Stock Compensation Pla

Note 9 - Stock Compensation Plans	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	9. Stock Compensation Plans The Company’s 2010 “2010 May 2010. 2010 May 17, 2011, 2010 February 2, 2012, 2010 April 25, 2012 May 23, 2017, 2010 2010 may not ten 2010 ten For the years ended December 31, 2023, 2022 2021 Stock Options Stock option awards provide holders the right to purchase shares of Common Stock at prices determined by the Compensation Committee, at the time of grant, and must have an exercise price equal to or in excess of the fair market value of the Company’s common stock at the date of grant. The fair value of options granted is estimated at the date of grant. Expected volatility has been estimated using the historical volatility of the Company's common stock using historical periods equivalent to the options’ expected lives. The expected dividend yield assumption reflects that the Company does not A summary of the Company’s stock option activity is as follows: Weighted Weighted Average Average Aggregate Number of Exercise Remaining Life Intrinsic Options Price (in years) Value Outstanding at January 1, 2023 (1) 226,896 $ 6.58 Granted 25,000 6.07 Exercised (28,796 ) 3.04 Canceled/Expired (28,796 ) 5.12 Outstanding at December 31, 2023 194,304 $ 6.51 7.88 $ 14,266 Vested at December 31, 2023 194,304 $ 6.51 7.88 $ 14,266 Exercisable at December 31, 2023 194,304 $ 6.51 7.88 $ 14,266 ( 1 January 1, 2023 December 31, 2022 2022 10 2023. 2010 As of December 31, 2023 December 31, 2023 2022 The stock options exercised during the year ended December 31, 2023 December 31, 2022 December 31, 2021. Restricted Stock Units RSUs awarded to employees vest on schedules of between one three one Weighted Average Number of Grant-Date RSUs Fair Value Outstanding at January 1, 2023 (1) 295,705 $ 8.56 Granted (2) 415,438 6.14 Vested and released (217,799 ) 8.77 Canceled/Expired (7,019 ) 7.63 Outstanding at December 31, 2023 (2) 486,325 $ 6.41 ( 1 ( 2 As of December 31, 2023 December 31, 2023 2022 2021 December 31, 2023, 2022 2021

Note 10 - Income Taxes

Note 10 - Income Taxes	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Income Tax Disclosure [Text Block]	10. Income Taxes The Company's provision (benefit) for income taxes comprises the following: For the year ended December 31, 2023 2022 2021 Current: Federal $ 23,698,658 $ 13,154,619 $ 19,211,782 State and local 792,477 897,285 513,753 Foreign 14,445 3,800 13,994 Total current provision 24,505,580 14,055,704 19,739,529 Deferred: Federal (4,711,556 ) (3,818,283 ) 89,947 State and local (86,177 ) (9,495 ) 31,499 Foreign — — — Total deferred (benefit) provision (4,797,733 ) (3,827,778 ) 121,446 Total provision $ 19,707,847 $ 10,227,926 $ 19,860,975 The Company’s deferred tax assets and liabilities comprise the following: As of December 31, 2023 2022 Deferred income tax assets: State net operating losses $ 1,194,814 $ 1,247,826 Inventory 777,146 336,333 Reserves and accruals 666,772 569,290 Amortization of intangible assets 7,852 24,532 Share-based compensation 506,451 510,058 Fixed Assets 34,546 — Deferred revenue 2,256,099 66,011 Capitalized R&D 6,198,455 4,194,106 Lease liability 319,074 443,902 Other 514,150 380,162 Deferred income tax assets 12,475,359 7,772,220 Less: valuation allowance (943,903 ) (985,783 ) Deferred income tax assets, net of valuation allowance $ 11,531,456 $ 6,786,437 Deferred income tax liabilities: Amortization of goodwill (192,130 ) (192,083 ) Property, plant and equipment — (59,727 ) Other (291,208 ) (284,242 ) Deferred income tax asset, net $ 11,048,118 $ 6,250,385 The recognition of a valuation allowance for deferred taxes requires management to make estimates and judgments about the Company’s future profitability which is inherently uncertain. The Company assesses all available positive and negative evidence to determine if its existing deferred tax assets are realizable on a more-likely-than- not December 31, 2023 not not December 31, 2023 The benefit for income taxes differs from the expected amount calculated by applying the Company's statutory rate to the income or loss before benefit for income taxes as follows: As of December 31, 2023 2022 2021 Statutory federal income tax rate 21.0% 21.0% 21.0% State and local taxes 0.1% 1.6% 0.5% Change in fair value of common stock warrant — (0.2)% — Section 162(m) limitation 0.4% 0.7% 0.5% Other 1.0% 0.1% 0.2% Effective tax rate 22.5% 23.2% 22.2% For the years ended December 31, 2023 2022 162 December 31, 2021 162 A reconciliation of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, is as follows: For the year ended December 31, 2023 2022 2021 Balance at beginning of year $ 5,103,548 $ 5,602,587 $ 5,591,587 Tax positions related to the current and prior years: Additions — — 11,000 Reductions (17,096 ) (68,792 ) — Settlements — — — Lapses in applicable statutes of limitation (4,842 ) (430,247 ) — Balance at the end of the year $ 5,081,610 $ 5,103,548 $ 5,602,587 Included in the balance of unrecognized tax benefits as of December 31, 2023 December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 no twelve December 31, 2023 The Company files federal income tax returns and income tax returns in various state and local tax jurisdictions. The federal tax years open to examination are 2020 to 2023 2023

Note 11 - Revenues by Geographi

Note 11 - Revenues by Geographic Region	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	11. Revenues by geographic region were as follows: For the year ended December 31, 2023 2022 2021 United States $ 118,650,253 $ 39,803,888 $ 120,656,294 International Asia-Pacific 966,633 14,853,233 — Canada — 38,875,657 13,014,160 Europe, Middle East and Africa (EMEA) 20,300,334 16,270,033 — Other — 972,799 — Total International 21,266,967 70,971,722 13,014,160 Total revenues $ 139,917,220 $ 110,775,610 $ 133,670,454

Note 12 - Commitments and Conti

Note 12 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	12. Commitments and Contingencies Operating lease commitments The Company leases its Corvallis, Oregon, facilities and office space under an operating lease which was signed on November 3, 2017 January 1, 2018. December 31, 2019, two one two three second 2019, first December 31, 2021. second 2021, second December 31, 2024. second second 2021. May 26, 2017 ten 31 62nd no Operating lease costs totaled $0.6 million for each of the years ended December 31, 2023 2022 December 31, 2023 2022 December 31, 2023 The following is a maturity analysis of the Company's lease liabilities as of December 31, 2023 2024 $ 622,638 2025 406,994 2026 409,971 2027 165,916 Total undiscounted cash flows under operating leases 1,605,519 Less: Imputed interest (113,642 ) Present value of lease liabilities $ 1,491,877 As of December 31, 2023 Legal Proceedings From time to time, we may not Purchase Commitments In the course of our business, the Company regularly enters into agreements with third not December 31, 2023

Note 13 - Related Party Transac

Note 13 - Related Party Transactions	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	13. Related Party Transactions Board of Directors and Outside Counsel A former member of the Company’s Board of Directors who did not 2021 not December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2023 2022 Effective June 13, 2023, December 31, 2023 December 31, 2023 Real Estate Leases On May 26, 2017, 31 62nd first sixty-three first six first sixty-fourth first second five December 31, 2023 December 31, 2023 2022

Note 14 - Subsequent Event

Note 14 - Subsequent Event	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Subsequent Events [Text Block]	14. Subsequent Event On March 12, 2024, April 11, 2024 March 26, 2024.

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2023
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]		Item 9B. None 10b5 1 10b5 1 December 31, 2023, 408
Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the periods reported. The most significant estimates include the variables used in the calculation of reported amounts of revenue recognized over time, and the valuation of deferred tax assets. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the financial statements in the period they are determined to be necessary. Actual results could differ from these estimates.
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation and Consolidation The accompanying consolidated financial statements include the accounts of SIGA Technologies, Inc. and its wholly owned subsidiaries. All inter-company accounts and transactions have been eliminated in consolidation. The consolidated financial statements and related disclosures are presented in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and reflect the consolidated financial position, results of operations and cash flows for all periods presented.
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassifications Certain reclassifications have been made to prior year amounts to conform to the current year's presentation.
Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]	Cash Equivalents The Company considers all highly liquid investments with original maturities of three
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk The Company has cash in bank accounts that exceeds the Federal Deposit Insurance Corporation insured limits. The Company has not no Collection of all receivables from international government sales is coordinated through the International Promotion Agreement with Meridian (see Note 3
Accounts Receivable [Policy Text Block]	Accounts Receivable Accounts receivable are recorded net of provisions for doubtful accounts. At December 31, 2023 2022 December 31, 2023 four a Note 3 December 31, 2023 2022
Inventory, Policy [Policy Text Block]	Inventory Inventory is stated at the lower of cost or net realizable value. The cost is determined using the first first may not
Property, Plant and Equipment, Policy [Policy Text Block]	Property, Plant and Equipment Property, plant and equipment are stated at cost, net of accumulated depreciation. Depreciation and amortization are provided on a straight-line method over the estimated useful lives of the various asset classes. The estimated useful lives are as follows: five three seven
Derivatives, Policy [Policy Text Block]	Warrant Liability The Company accounted for warrants in accordance with the authoritative guidance which requires that free-standing derivative financial instruments with certain cash settlement features be classified as assets or liabilities at the time of the transaction, and recorded at their fair value. Fair value was estimated using model-derived valuations. Any changes in the fair value of the derivative instruments were reported in earnings or loss as long as the derivative contracts were classified as assets or liabilities. During 2022, December 31, 2022. The following table presents changes in the liability-classified warrant: Fair Value of liability-classified warrant Warrant liability at December 31, 2021 $ 6,521,441 Decrease in fair value of warrant liability (400,663 ) Exercise of warrants (6,120,778 ) Warrant liability at December 31, 2022 $ -
Revenue [Policy Text Block]	Revenue Recognition The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers 606” Performance Obligations 606. December 31, 2023 Note 3 Contract modifications may not The Company’s performance obligations are satisfied over time as work progresses or at a point in time. A portion of the Company’s revenue is derived from long-term contracts that span multiple years. All of the Company’s revenue related to current research and development performance obligations is recognized over time, because the customer simultaneously receives and consumes the benefits provided by the services as the Company performs these services. The Company recognizes revenue related to these services based on the progress toward complete satisfaction of the performance obligation and measures this progress under an input method, which is based on the Company’s cost incurred relative to total estimated costs. Under this method, progress is measured based on the cost of resources consumed (i.e., cost of third third Contract Estimates Contract estimates are based on various assumptions to project the outcome of future events that often span multiple years. These assumptions include: labor productivity; the complexity of the work to be performed; external factors such as customer behavior and potential regulatory outcomes; and the performance of subcontractors, among other variables. The nature of the work required to be performed on many of the Company’s performance obligations and the estimation of total revenue and cost at completion may not not A significant change in one Contract Balances may December 31, 2023 December 31, 2023 Remaining Performance Obligations not December 31, 2023 three
Lessee, Leases [Policy Text Block]	Leases The Company accounts for leases in accordance with ASC 842, Leases 842” The Company determines if an arrangement is a lease at inception. Leases with an initial term less than one not one Operating lease liabilities are recognized at the commencement date based on the present value of future minimum lease payments over the lease term. ROU assets are recognized based on the corresponding lease liabilities adjusted for qualifying initial direct costs, prepaid or accrued lease payments and unamortized lease incentives. The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease. Lease terms may
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development expenses include costs directly and indirectly attributable to the conduct of research and development programs, and performance pursuant to certain customer contracts, including employee related costs, materials, supplies, depreciation and maintenance of equipment, the cost of services provided by outside contractors, including services related to the Company’s clinical trials and facility costs, such as rent, utilities, and general support services. All costs associated with research and development are expensed as incurred. Costs related to the acquisition of technology rights, for which development work is still in process, and that have no
Goodwill and Intangible Assets, Policy [Policy Text Block]	Goodwill The Company evaluates goodwill for impairment at least annually or as circumstances warrant. The impairment review process compares the fair value of the reporting unit in which goodwill resides to its carrying value. The Company operates as one one
Share-Based Payment Arrangement [Policy Text Block]	Share-based Compensation Stock-based compensation expense for all share-based payment awards made to employees and directors is determined on the grant date; for option awards, fair value was estimated using the Black-Scholes model. These compensation costs are recognized net of an estimated forfeiture rate over the requisite service periods of the awards. Forfeitures are estimated on the date of the respective grant and revised if actual or expected forfeiture activity differs from original estimates. The fair value of cash-settled restricted stock unit ("RSU") awards is determined by the value of our common stock and is recognized based on the portion of the requisite service period satisfied as of each valuation date. The fair valuation of the cash-settled awards changes based on changes in our common stock price. The portion of cash-settled RSUs that is recognized based on service period is reflected in accrued expenses and other current liabilities in our consolidated balance sheet. Increases (or decreases) in accrued expenses result in adjustments to earnings for the associated valuation updates.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company recognizes income taxes utilizing the asset and liability method of accounting for income taxes. Under this method, deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities at enacted tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is established if it is more likely than not not may not fifty not
Stockholders' Equity, Policy [Policy Text Block]	Repurchase of shares When shares recognized as equity are repurchased, the amount of the consideration paid, which includes directly attributable costs, is recognized as a deduction from equity. The excess of the purchase price above par value of repurchased shares that are retired is presented as an increase to accumulated deficit (or a reduction of retained earnings, if any).
Earnings Per Share, Policy [Policy Text Block]	Earnings (Loss) per Share Basic earnings per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the period, assuming potentially dilutive common shares from option exercises, RSUs, warrants and other incentives had been issued and any proceeds received in respect thereof were used to repurchase common stock at the average market price during the period. The assumed proceeds used to repurchase common stock is the sum of the amount to be paid to the Company upon exercise of options and warrants and the amount of compensation cost attributed to future services not
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The carrying value of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and other current liabilities approximates fair value due to the relatively short maturity of these instruments. The measurement of fair value requires the use of techniques based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions. The inputs create the following fair value hierarchy: • Level 1 • Level 2 not • Level 3 third There were no 2023 2022 December 31, 2023 December 31, 2022 1 no 2 December 31, 2023 December 31, 2022 2 no 3 December 31, 2023 December 31, 2022 For the years ended December 31, 2023, 2022 2021
Commitments and Contingencies, Policy [Policy Text Block]	Loss Contingencies The Company is subject to certain contingencies arising in the ordinary course of business. The Company records accruals for these contingencies to the extent that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, that amount is accrued. Alternatively, when no
Segment Reporting, Policy [Policy Text Block]	Segment Information The Company is managed and operated as one not not one
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In November 2023, No. 2023 07, 280 not December 15, 2023, December 15, 2024, no In December 2023, 2023 09, 2023 09 December 15, 2024, may not

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Fair Value of liability-classified warrant Warrant liability at December 31, 2021 $ 6,521,441 Decrease in fair value of warrant liability (400,663 ) Exercise of warrants (6,120,778 ) Warrant liability at December 31, 2022 $ -

Note 4 - Inventory (Tables)

Note 4 - Inventory (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Inventory, Current [Table Text Block]	As of December 31, 2023 December 31, 2022 Raw materials $ 8,061,800 $ 6,370,581 Work in-process 53,649,859 27,038,845 Finished goods 2,506,678 5,863,664 Inventory $ 64,218,337 $ 39,273,090

Note 5 - Property, Plant and _2

Note 5 - Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Property, Plant and Equipment [Table Text Block]	As of December 31, 2023 December 31, 2022 Leasehold improvements $ 2,420,028 $ 2,420,028 Computer equipment 468,937 449,143 Furniture and fixtures 347,045 347,045 Operating lease right-of-use asset 3,678,647 3,678,647 6,914,657 6,894,863 Less-accumulated depreciation (5,582,949 ) (5,046,549 ) Property, plant and equipment, net $ 1,331,708 $ 1,848,314

Note 6 - Accrued Expenses and_2

Note 6 - Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	As of December 31, 2023 December 31, 2022 Inventory $ 3,300,985 $ 31,160 Compensation 2,792,874 2,378,035 Other 2,659,608 1,277,779 Lease liability, current portion 564,009 528,170 Professional fees 445,653 536,997 Research and development vendor costs 418,681 1,551,920 Accrued expenses and other current liabilities $ 10,181,810 $ 6,304,061

Note 7 - Per Share Data (Tables

Note 7 - Per Share Data (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended December 31, 2023 2022 2021 Net income for basic earnings per share $ 68,068,826 $ 33,904,806 $ 69,450,766 Less: Change in fair value of warrants — 400,663 117,770 Net income, adjusted for change in fair value of warrants for diluted earnings per share $ 68,068,826 $ 33,504,143 $ 69,332,996 Weighted-average shares 71,362,209 72,929,550 75,322,194 Effect of potential common shares 317,061 616,951 1,080,522 Weighted-average shares: diluted 71,679,270 73,546,501 76,402,716 Earnings per share: basic $ 0.95 $ 0.46 $ 0.92 Earnings per share: diluted $ 0.95 $ 0.46 $ 0.91

Note 9 - Stock Compensation P_2

Note 9 - Stock Compensation Plans (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Weighted Average Average Aggregate Number of Exercise Remaining Life Intrinsic Options Price (in years) Value Outstanding at January 1, 2023 (1) 226,896 $ 6.58 Granted 25,000 6.07 Exercised (28,796 ) 3.04 Canceled/Expired (28,796 ) 5.12 Outstanding at December 31, 2023 194,304 $ 6.51 7.88 $ 14,266 Vested at December 31, 2023 194,304 $ 6.51 7.88 $ 14,266 Exercisable at December 31, 2023 194,304 $ 6.51 7.88 $ 14,266
Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]	Weighted Average Number of Grant-Date RSUs Fair Value Outstanding at January 1, 2023 (1) 295,705 $ 8.56 Granted (2) 415,438 6.14 Vested and released (217,799 ) 8.77 Canceled/Expired (7,019 ) 7.63 Outstanding at December 31, 2023 (2) 486,325 $ 6.41

Note 10 - Income Taxes (Tables)

Note 10 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	For the year ended December 31, 2023 2022 2021 Current: Federal $ 23,698,658 $ 13,154,619 $ 19,211,782 State and local 792,477 897,285 513,753 Foreign 14,445 3,800 13,994 Total current provision 24,505,580 14,055,704 19,739,529 Deferred: Federal (4,711,556 ) (3,818,283 ) 89,947 State and local (86,177 ) (9,495 ) 31,499 Foreign — — — Total deferred (benefit) provision (4,797,733 ) (3,827,778 ) 121,446 Total provision $ 19,707,847 $ 10,227,926 $ 19,860,975
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	As of December 31, 2023 2022 Deferred income tax assets: State net operating losses $ 1,194,814 $ 1,247,826 Inventory 777,146 336,333 Reserves and accruals 666,772 569,290 Amortization of intangible assets 7,852 24,532 Share-based compensation 506,451 510,058 Fixed Assets 34,546 — Deferred revenue 2,256,099 66,011 Capitalized R&D 6,198,455 4,194,106 Lease liability 319,074 443,902 Other 514,150 380,162 Deferred income tax assets 12,475,359 7,772,220 Less: valuation allowance (943,903 ) (985,783 ) Deferred income tax assets, net of valuation allowance $ 11,531,456 $ 6,786,437 Deferred income tax liabilities: Amortization of goodwill (192,130 ) (192,083 ) Property, plant and equipment — (59,727 ) Other (291,208 ) (284,242 ) Deferred income tax asset, net $ 11,048,118 $ 6,250,385
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	As of December 31, 2023 2022 2021 Statutory federal income tax rate 21.0% 21.0% 21.0% State and local taxes 0.1% 1.6% 0.5% Change in fair value of common stock warrant — (0.2)% — Section 162(m) limitation 0.4% 0.7% 0.5% Other 1.0% 0.1% 0.2% Effective tax rate 22.5% 23.2% 22.2%
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	For the year ended December 31, 2023 2022 2021 Balance at beginning of year $ 5,103,548 $ 5,602,587 $ 5,591,587 Tax positions related to the current and prior years: Additions — — 11,000 Reductions (17,096 ) (68,792 ) — Settlements — — — Lapses in applicable statutes of limitation (4,842 ) (430,247 ) — Balance at the end of the year $ 5,081,610 $ 5,103,548 $ 5,602,587

Note 11 - Revenues by Geograp_2

Note 11 - Revenues by Geographic Region (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Revenue from External Customers by Geographic Areas [Table Text Block]	For the year ended December 31, 2023 2022 2021 United States $ 118,650,253 $ 39,803,888 $ 120,656,294 International Asia-Pacific 966,633 14,853,233 — Canada — 38,875,657 13,014,160 Europe, Middle East and Africa (EMEA) 20,300,334 16,270,033 — Other — 972,799 — Total International 21,266,967 70,971,722 13,014,160 Total revenues $ 139,917,220 $ 110,775,610 $ 133,670,454

Note 12 - Commitments and Con_2

Note 12 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	2024 $ 622,638 2025 406,994 2026 409,971 2027 165,916 Total undiscounted cash flows under operating leases 1,605,519 Less: Imputed interest (113,642 ) Present value of lease liabilities $ 1,491,877

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual)	1 Months Ended			12 Months Ended
	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Accounts Receivable, Allowance for Credit Loss	$ 0	$ 0		$ 0	$ 0
Contract with Customer, Asset, after Allowance for Credit Loss	10,300,000			10,300,000
Contract with Customer, Liability, Revenue Recognized				100,000
Revenue, Remaining Performance Obligation, Amount	92,100,000			$ 92,100,000
Number of Operating Segments				1
Number of Reporting Units				1
Nonoperating Income (Expense)	4,200,000	1,000,000	$ 100,000	$ 4,155,508	1,031,903	$ 101,172
Number of Reportable Segments				1
Fair Value, Inputs, Level 1 [Member]
Cash and Cash Equivalents, Fair Value Disclosure	95,100,000	100,000		$ 95,100,000	100,000
Fair Value, Inputs, Level 2 [Member]
Cash and Cash Equivalents, Fair Value Disclosure	$ 0	$ 40,500,000		$ 0	$ 40,500,000
Research and Development [Member]
Revenue, Performance Obligation, Number of Obligations	5			5
Manufacture and Delivery [Member]
Revenue, Performance Obligation, Number of Obligations	5			5
The 2016 Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0			0
Laboratory Equipment [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years			5 years
Computer Equipment [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years			3 years
Furniture and Fixtures [Member]
Property, Plant and Equipment, Useful Life (Year)	7 years			7 years
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Non-US [Member]
Concentration Risk, Percentage				47%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | US Government [Member]
Concentration Risk, Percentage				53%	16%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | European Government [Member]
Concentration Risk, Number of Customers				4
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Asia Pacific Government [Member]
Concentration Risk, Number of Customers				1

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Change in Level 3 Liability (Details)	12 Months Ended
	Dec. 31, 2022 USD ($)
Warrant liability at December 31, 2021	$ 6,521,441
Decrease in fair value of warrant liability	(400,663)
Exercise of warrants	(6,120,778)
Warrant liability at December 31, 2022	$ 0

Note 3 - Procurement Contract_2

Note 3 - Procurement Contracts and Research Agreements (Details Textual) $ in Millions					1 Months Ended	2 Months Ended	3 Months Ended				12 Months Ended
	Feb. 29, 2024 USD ($)	Sep. 28, 2022 USD ($)	May 12, 2022 USD ($)	Sep. 10, 2018 USD ($)	Dec. 31, 2023 USD ($)	Feb. 29, 2024 USD ($)	Dec. 31, 2023 USD ($)	Mar. 31, 2023 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Oct. 31, 2023	Dec. 31, 2021 USD ($)	Jul. 31, 2019 USD ($)
Contract with Customer, Liability, Revenue Recognized											$ 0.1
The 19C BARDA Contract [Member]
Number of Courses to Be Delivered				1,488,000									106,000
Number of Vials in a Course				14									28
Government Contract, Value of Award					$ 602.5		$ 602.5				602.5
Government Contract, Base Period, Value of Award for Delivery and Support Activities				$ 51.7	51.7		51.7				51.7
Government Contract Value Related To Exercised Options											407.1
Government Contract, Value, Payments Currently Specified as Unexercised Options											$ 143.7
Base Period of Performance, Exercise of Options, Term (Year)											10 years
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Delivery of Courses				$ 11.1
Government Contract, Base Period, Number of Deliveries				35,700
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Manufacture of Courses				$ 8
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Advanced Development				32
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Supportive Procurement Activities				0.6
Proceeds from Delivery of Courses											$ 11.1
Number of Courses Delivered											35,700
Proceeds from Other Base Period Activities											$ 22.1
Government Contract, Value, Payments Remaining Related to Exercised Options											407.1
Government Contract, Value of Unexercised Options, Supportive Procurement Activities					5.6		5.6				5.6
The 19C BARDA Contract [Member] | Transferred over Time [Member]
Contract with Customer, Liability, Revenue Recognized											97.9
The 19C BARDA Contract [Member] | Transferred at Point in Time [Member]
Contract with Customer, Liability, Revenue Recognized												$ 7.2
The 19C BARDA Contract [Member] | IV TPOXX [Member]
Number of Courses to Be Delivered													10,000
Government Contract, Value, Payments Related to Exercised Options, Funding of Post-Marketing Activities					3.6		3.6				3.6
Government Contract, Value, Payments Related to Unexercised Options, Delivery of Courses					112.5		112.5				112.5
Government Contract, Value, Payments Related to Unexercised Options, Funding of Post-Marketing Activities					$ 10.2		$ 10.2				$ 10.2
Number of Manufacturing Steps					2		2				2
The 19C BARDA Contract [Member] | IV BDS [Member]
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Manufacture of Courses				$ 3.2
Proceeds from the Manufacture of Courses											$ 3.2
Proceeds from the Delivery of Courses											4.3
Contract with Customer, Liability, Total					$ 20.5		$ 20.5				$ 20.5			$ 3.2
Government Contract, Number of Options for Manufacture of Product					3		3				3
Government Contract, Courses Manufactured Upon Exercise of Options					32,000		32,000				32,000
The 19C BARDA Contract [Member] | IV FDP Containing IV BDS [Member]
Contract with Customer, Liability, Total					$ 20.4		$ 20.4				$ 20.4	0.3
Contract with Customer, Liability, Revenue Recognized												2.9
Government Contract, Value, Payments Currently Specified as Unexercised Options, Manufacture of Courses					$ 51.2		$ 51.2				$ 51.2
The 19C BARDA Contract [Member] | Oral TPOXX [Member]
Number of Courses to Be Delivered					1,100,000		1,100,000				1,100,000
Government Contract, Value, Payments Related to Exercised Options, Delivery of Courses					$ 337.7		$ 337.7				$ 337.7
Government Contract, Value, Payments Related to Exercised Options, Funding of Post-Marketing Activities					14.6		14.6				14.6
Government Contract, Total Amount of Exercised Options, Delivery of Materials							97.9				323
Proceeds from Payments Received for Post-marketing Activities											7.9
The 19C BARDA Contract [Member] | Oral TPOXX [Member] | Subsequent Event [Member]
Government Contract, Total Amount of Exercised Options, Delivery of Materials						$ 15
The 19C BARDA Contract [Member] | IV FDP [Member]
Government Contract, Value, Payments Currently Specified as Unexercised Options, Manufacture of Courses					$ 25.6		$ 25.6				$ 25.6
Government Contract, Number of Options for Manufacture of Product					3		3				3
Government Contract, Courses Manufactured Upon Exercise of Options					32,000		32,000				32,000
The 19C BARDA Contract [Member] | Maximum [Member]
Number of Courses to Be Delivered				212,000
IC BARDA [Member] | Transferred over Time [Member]
Contract with Customer, Liability, Revenue Recognized											$ 3	6.2
Government Contract, Value, Payments Currently Specified as Unexercised Options, Manufacture of Courses					$ 10.2		$ 10.2				10.2
Government Contract, Value, Payments Related to Unexercised Options, Funding of Post-Marketing Activities					25.6		25.6				25.6
U.S. Department of Defense (“DoD”) [Member] | Oral TPOXX [Member]
Government Contract, Value, Payments Currently Specified as Unexercised Options		$ 5.5	$ 3.8
Contract with Customer, Liability, Revenue Recognized							5.5	$ 5.1		$ 3.6
Government Contract, Value Ordered		$ 5.1	$ 3.6
Government Contract, Value, Option Exercised								$ 5.5	$ 3.8
U.S. Department of Defense (“DoD”) [Member] | Oral TPOXX [Member] | Subsequent Event [Member]
Government Contract, Value Ordered	$ 1					1
International Procurement [Member]
Contract with Customer, Liability, Revenue Recognized											21.3	71
International Procurement [Member] | Oral TPOXX [Member]
Government Contract, Value of Award												77
Government Contract, Value, Payments Currently Specified as Unexercised Options					6.7
Contract with Customer, Liability, Revenue Recognized												71
Government Contract, Value Ordered					21.3		21.3				21.3
International Procurement [Member] | Oral TPOXX [Member] | CANADA
Government Contract, Value of Award												39
International Procurement [Member] | Oral TPOXX [Member] | Europe, Asia Pacific and the Middle East [Member]
Government Contract, Value of Award												38
International Procurement [Member] | Oral TPOXX [Member] | Scenario, Plan [Member]
Government Contract, Value of Award					$ 14		$ 14				14
International Procurement [Member] | Oral TPOXX [Member] | Subsequent Event [Member]
Government Contract, Value of Award	18					18
Government Contract, Delivery of Material	$ 7					7
Percentage of Deliveries Completed	95%
Canadian Contract [Member] | Subsequent Event [Member] | Meridian Medical Technologies [Member]
Government Contract, Delivery of Material	$ 0.7					$ 0.7
The PEP Label Expansion R & D Contract with the Department of Defense [Member]
Contract with Customer, Liability, Revenue Recognized											$ 6.4	$ 17.9
Government Contract, Increased Value of Award															$ 27

Note 4 - Inventory - Inventory

Note 4 - Inventory - Inventory (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Raw materials	$ 8,061,800	$ 6,370,581
Work in-process	53,649,859	27,038,845
Finished goods	2,506,678	5,863,664
Inventory	$ 64,218,337	$ 39,273,090

Note 5 - Property, Plant and _3

Note 5 - Property, Plant and Equipment (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Depreciation, Depletion and Amortization	$ 538,293	$ 517,643	$ 522,368

Note 5 - Property, Plant and _4

Note 5 - Property, Plant and Equipment - Property, Plant and Equipment (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Property, plant and equipment, gross	$ 6,914,657	$ 6,894,863
Less-accumulated depreciation	(5,582,949)	(5,046,549)
Property, plant and equipment, net	1,331,708	1,848,314
Other Assets [Member]
Property, plant and equipment, gross	3,678,647	3,678,647
Leasehold Improvements [Member]
Property, plant and equipment, gross	2,420,028	2,420,028
Computer Equipment [Member]
Property, plant and equipment, gross	468,937	449,143
Furniture and Fixtures [Member]
Property, plant and equipment, gross	$ 347,045	$ 347,045

Note 6 - Accrued Expenses - Acc

Note 6 - Accrued Expenses - Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Inventory	$ 3,300,985	$ 31,160
Compensation	2,792,874	2,378,035
Other	2,659,608	1,277,779
Professional fees	445,653	536,997
Research and development vendor costs	418,681	1,551,920
Accrued expenses and other current liabilities	10,181,810	6,304,061
Accrued Expenses and Other Current Liabilities [Member]
Lease liability, current portion	$ 564,009	$ 528,170

Note 7 - Per Share Data (Detail

Note 7 - Per Share Data (Details Textual) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	32,660	17,388	29,873

Note 7 - Per Share Data - Recon

Note 7 - Per Share Data - Reconciliation of the Basic and Diluted Loss Per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Net income	$ 68,068,826	$ 33,904,806	$ 69,450,766
Less: Change in fair value of warrants	0	400,663	117,770
Net income, adjusted for change in fair value of warrants for diluted earnings per share	$ 68,068,826	$ 33,504,143	$ 69,332,996
Weighted-average shares (in shares)	71,362,209	72,929,550	75,322,194
Effect of potential common shares (in shares)	317,061	616,951	1,080,522
Weighted-average shares: diluted (in shares)	71,679,270	73,546,501	76,402,716
Basic earnings per share (in dollars per share)	$ 0.95	$ 0.46	$ 0.92
Diluted earnings per share (in dollars per share)	$ 0.95	$ 0.46	$ 0.91

Note 8 - Stockholders' Equity (

Note 8 - Stockholders' Equity (Details Textual) - USD ($)		12 Months Ended
	May 04, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Aug. 02, 2021
Capital Units, Authorized (in shares)		620,000,000
Common Stock, Shares Authorized (in shares)		600,000,000	600,000,000
Preferred Stock, Shares Authorized (in shares)		20,000,000
Preferred Stock, Shares Outstanding (in shares)		0	0
Stock Repurchase Program, Authorized Amount					$ 50,000,000
Stock Repurchased During Period, Value		$ 11,072,511	$ 13,006,331	$ 26,021,519
Preferred Stock, Shares Issued (in shares)		0	0
Special Dividend [Member]
Common Stock, Dividends, Per Share, Declared (in dollars per share)	$ 0.45
Dividends	$ 32,000,000
New Repurchase Authorization [Member]
Stock Repurchased During Period, Shares (in shares)		1,700,000
Stock Repurchased During Period, Value		$ 11,000,000
Excise Tax on Corporate Shares Repurchased		$ 100,000

Note 9 - Stock Compensation P_3

Note 9 - Stock Compensation Plans (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	May 23, 2017	Apr. 25, 2012	May 17, 2011
Share-Based Payment Arrangement, Expense	$ 2,100,000	$ 1,800,000	$ 1,300,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value	$ 123,000	$ 375,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)	100,000	0
Stock Options [Member]
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount	$ 0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)	28,796
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding Number to be Settled in Cash (in shares)	30,702
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Number to be Settled in Cash (in shares)	59,309
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount	$ 1,500,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	9 months 18 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)	$ 6.14	$ 9.4	$ 6.95
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	$ 1,900,000	$ 1,200,000	$ 900,000
Restricted Stock Units (RSUs) [Member] | Director [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	1 year
Restricted Stock Units (RSUs) [Member] | Share-Based Payment Arrangement, Employee [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	1 year
Restricted Stock Units (RSUs) [Member] | Share-Based Payment Arrangement, Employee [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	3 years
The 2010 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)				8,500,000	4,500,000	2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years

Note 9 - Stock Compensation P_4

Note 9 - Stock Compensation Plans - Stock Options Activity (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022
Exercised (in shares)		(100,000)	0
Stock Options [Member]
Outstanding (in shares)	[1]	226,896
Outstanding, weighted average exercise price (in dollars per share)		$ 6.58
Granted (in shares)		25,000
Granted, weighted average exercise price (in dollars per share)		$ 6.07
Exercised (in shares)		(28,796)
Exercised, weighted average exercise price (in dollars per share)		$ 3.04
Canceled/Expired (in shares)		(28,796)
Canceled/Expired, weighted average exercise price (in dollars per share)		$ 5.12
Outstanding (in shares)		194,304	226,896	[1]
Outstanding, weighted average exercise price (in dollars per share)		$ 6.51	$ 6.58
Outstanding, weighted average remaining life (Year)		7 years 10 months 17 days
Outstanding, aggregate intrinsic value		$ 14,266
Vested (in shares)		194,304
Vested, weighted average exercise price (in dollars per share)		$ 6.51
Vested, weighted average remaining life (Year)		7 years 10 months 17 days
Vested, aggregate intrinsic value		$ 14,266
Exercisable (in shares)		194,304
Exercisable, weighted average exercise price (in dollars per share)		$ 6.51
Exercisable, weighted average remaining life (Year)		7 years 10 months 17 days
Exercisable, aggregate intrinsic value		$ 14,266
[1]Balances as of January 1, 2023 differ from those as of December 31, 2022 presented in the Company's 2022 Form 10-K due to the special dividend paid during 2023. In connection with the dividend, the number of options and the weighted average exercise price were adjusted pursuant to the terms of the Company's 2010 Plan.

Note 9 - Stock Compensation P_5

Note 9 - Stock Compensation Plans - Restricted Stock and Restricted Stock Units (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares		12 Months Ended
		Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021
Outstanding (in shares)	[1]	295,705
Outstanding, weighted average grant date fair value (in dollars per share)		$ 8.56
Granted (in shares)	[2]	415,438
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)		$ 6.14		$ 9.4		$ 6.95
Vested and released (in shares)		(217,799)
Vested and released, weighted average grant date fair value (in dollars per share)		$ 8.77
Canceled/Expired (in shares)		(7,019)
Canceled/Expired, weighted average grant date fair value (in dollars per share)		$ 7.63
Outstanding (in shares)		486,325	[2]	295,705	[1]
Outstanding, weighted average grant date fair value (in dollars per share)		$ 6.41		$ 8.56
[1]includes 30,702 awards which were settled in cash.[2]includes 59,309 awards which were expected to be settled in cash.

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual) - USD ($)		12 Months Ended
	Jan. 01, 2021	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount		$ 42,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21%	21%	21%	21%
Unrecognized Tax Benefits that Would Impact Effective Tax Rate		$ 5,100,000
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued		214,000	$ 72,000
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense		$ 142,000	$ (23,000)
Domestic Tax Authority [Member]
Open Tax Year		2020
State and Local Jurisdiction [Member]
Open Tax Year		2019

Note 10 - Income Taxes - Compon

Note 10 - Income Taxes - Components of Income Tax Expense Benefit (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Federal	$ 23,698,658	$ 13,154,619	$ 19,211,782
State and local	792,477	897,285	513,753
Foreign, current	14,445	3,800	13,994
Total current provision	24,505,580	14,055,704	19,739,529
Federal	(4,711,556)	(3,818,283)	89,947
State and local	(86,177)	(9,495)	31,499
Foreign, deferred	0	0	0
Total deferred (benefit) provision	(4,797,733)	(3,827,778)	121,446
Total provision	$ 19,707,847	$ 10,227,926	$ 19,860,975

Note 10 - Income Taxes - Deferr

Note 10 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
State net operating losses	$ 1,194,814	$ 1,247,826
Inventory	777,146	336,333
Reserves and accruals	666,772	569,290
Amortization of intangible assets	7,852	24,532
Share-based compensation	506,451	510,058
Fixed Assets	34,546	0
Deferred revenue	2,256,099	66,011
Capitalized R&D	6,198,455	4,194,106
Lease liability	319,074	443,902
Other	514,150	380,162
Deferred income tax assets	12,475,359	7,772,220
Less: valuation allowance	(943,903)	(985,783)
Deferred income tax assets, net of valuation allowance	11,531,456	6,786,437
Amortization of goodwill	(192,130)	(192,083)
Property, plant and equipment	0	(59,727)
Other	(291,208)	(284,242)
Deferred income tax asset, net	$ 11,048,118	$ 6,250,385

Note 10 - Income Taxes - Effect

Note 10 - Income Taxes - Effective Tax Rate Reconciliation (Details)		12 Months Ended
	Jan. 01, 2021	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21%	21%	21%	21%
State and local taxes		0.10%	1.60%	0.50%
Change in fair value of common stock warrant			(0.20%)
Section 162(m) limitation		0.40%	0.70%	0.50%
Other		1%	0.10%	0.20%
Effective tax rate		22.50%	23.20%	22.20%

Note 10 - Income Taxes - Unreco

Note 10 - Income Taxes - Unrecognized Tax Benefits Roll Forward (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Balance at beginning of year	$ 5,103,548	$ 5,602,587	$ 5,591,587
Additions	0	0	11,000
Reductions	(17,096)	(68,792)	0
Settlements	0	0	0
Lapses in applicable statutes of limitation	(4,842)	(430,247)	0
Balance at the end of the year	$ 5,081,610	$ 5,103,548	$ 5,602,587

Note 11 - Revenues by Geograp_3

Note 11 - Revenues by Geographic Region - Revenues by Geographic Region (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Total revenues	$ 139,917,220	$ 110,775,610	$ 133,670,454
UNITED STATES
Total revenues	118,650,253	39,803,888	120,656,294
Asia Pacific [Member]
Total revenues	966,633	14,853,233	0
CANADA
Total revenues	0	38,875,657	13,014,160
EMEA [Member]
Total revenues	20,300,334	16,270,033	0
Other [Member]
Total revenues	0	972,799	0
Non-US [Member]
Total revenues	$ 21,266,967	$ 70,971,722	$ 13,014,160

Note 12 - Commitments and Con_3

Note 12 - Commitments and Contingencies (Details Textual) $ in Millions		3 Months Ended	12 Months Ended
	Jan. 01, 2018	Jun. 30, 2021 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	May 26, 2017 ft²
Operating Lease, Cost			$ 0.6	$ 0.6
Operating Lease, Payments			$ 0.7	$ 0.6
Operating Lease, Weighted Average Remaining Lease Term (Year)			2 years 10 months 13 days
Operating Lease, Weighted Average Discount Rate, Percent			4.53%
Purchase Commitment, Remaining Minimum Amount Committed			$ 14.8
Other Liabilities [Member]
Operating Lease, Liability, Noncurrent			$ 0.9
Two Years, Option Renewal Term [Member] | Facilities and Office Space in Corvallis Oregon [Member]
Lessee, Operating Lease, Number of Renewal Options	2
Lessee, Operating Lease, Renewal Term (Year)	2 years
Increase (Decrease) in Operating Right-of-use Assets		$ 0.7
Three Years, Option RenewalTerm [Member] | Facilities and Office Space in Corvallis Oregon [Member]
Lessee, Operating Lease, Renewal Term (Year)	3 years
The New HQ Lease [Member] | MacAndrews and Forbes Incorporated [Member]
Lessee, Operating Lease, Term of Contract (Year)					10 years
Area of Real Estate Property (Square Foot) | ft²					3,200

Note 12 - Commitments and Con_4

Note 12 - Commitments and Contingencies - Maturity of Lease Liabilities (Details)	Dec. 31, 2023 USD ($)
2024	$ 622,638
2025	406,994
2026	409,971
2027	165,916
Total undiscounted cash flows under operating leases	1,605,519
Less: Imputed interest	(113,642)
Other Liabilities [Member]
Present value of lease liabilities	$ 1,491,877

Note 13 - Related Party Trans_2

Note 13 - Related Party Transactions (Details Textual)		12 Months Ended
	May 26, 2017 USD ($) ft²	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Director [Member]
Accounts Payable and Accrued Liabilities		$ 0
Consulting Agreement, Monthly Fee		20,000
Consulting Expense		240,000
Outside Counsel [Member]
Legal Fees		0	$ 0	$ 100,000
Accounts Payable and Accrued Liabilities		0
MacAndrews and Forbes Incorporated [Member] | The New HQ Lease [Member]
Accounts Payable and Accrued Liabilities		0	$ 0
Area of Real Estate Property (Square Foot) | ft²	3,200
Monthly Rent During Initial Period	$ 25,333
Monthly Rent, Initial Period (Month)	63 months
Monthly Rent After Initial Period	$ 29,333
Monthly Facility Fee, Second Year	$ 3,333
Monthly Facility Fee, Yearly Rate Increase After Second Year	5%
Monthly Facility Fee, Final Year	$ 4,925
Operating Lease, Expense		$ 400,000

Note 14 - Subsequent Event (Det

Note 14 - Subsequent Event (Details Textual) - Special Dividend [Member] - $ / shares	Mar. 12, 2024	May 04, 2023
Common Stock, Dividends, Per Share, Declared (in dollars per share)		$ 0.45
Subsequent Event [Member]
Common Stock, Dividends, Per Share, Declared (in dollars per share)	$ 0.6